Projections of Public Spending on Pharmaceuticals: A Review of Methods.

BACKGROUND

Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data. The objective of this review is to describe the methods for projections of pharmaceutical expenditure that apply the "bottom-up" approach and to synthesize the knowledge of their predictive accuracy.

METHODS

Projections of public pharmaceutical expenditure applicable to Western economies including a comprehensive method description and published 2000-2024 were searched in scientific databases (MEDLINE, EMBASE, and EconLit) and in gray literature (websites of international health organizations and national healthcare authorities). The data sources, assumptions about the future market dynamics, analytical approaches, and the projection results are summarized.

RESULTS

Twenty-four out of 3492 screened publications were included, associated with nine expenditure projection models. Four models were developed for all reimbursable drugs in the USA, the UK, the Stockholm region (Sweden), and seven European Union (EU) countries: France, Germany, Greece, Hungary, Poland, Portugal, and the UK, respectively. The other five models concerned specific groups of medicines: orphan drugs in Belgium, the Eurozone plus the UK, and Canada, respectively; psychotropic medications in the USA; and outpatient intravenous cancer medicines in the Province of Ontario (Canada). For trend analysis, drug coverage claims or sales data were used, applying linear and/or nonlinear models. The budget impact of new launches and patent expirations was estimated through (a form of) horizon scanning, i.e., a systematic monitoring of the pharmaceutical pipeline, with engagement of clinical expert judgment. Projections with a predictive time window greater than 3 years largely relied on previously observed trends to model new market introductions. Four models were validated through an ex post comparison of projected and observed expenditure. The absolute difference between the forecasted and actual percentual change in pharmaceutical expenditure was: 0.3% ("UK model"), 1.9% ("Stockholm model"), and 2% (nonfederal hospitals, "US model"). The "Ontario cancer drug model" overestimated the actual expenditure by 1%. Overall, the largest errors were attributable to new market launches and unforeseen policy reforms. Prediction accuracy decreased substantially for forecasts beyond 1 year in the future. For two not validated projections, a face validity check was feasible. One of the models forecasted a decrease in pharmaceutical expenditure from 2012 to 2016 in six European countries, contrasting with the currently available statistics. A 10-year projection of orphan drug expenditure underestimated the number of rare diseases treated in Europe by over 100%.

CONCLUSIONS

Published projections of national pharmaceutical expenditure are scarce and marked by significant methodological variability. Short-term forecasts based on high-quality historical data and rigorous horizon scanning tend to be more accurate than long-term forecasts built on theoretical assumptions. The combination of mathematical algorithms and expert judgment should be further explored, to increase the accuracy and efficiency of pharmaceutical expenditure projections.